Real-World Evaluation Screening Study and Registry of Dyskinesia in Patients Taking Antipsychotic Agents (RE-Kinect)

Neurocrine Biosciences

Status: Unknown

Conditions: Tardive Dyskinesia

Study type: Observational

Funder types: Industry

Identifiers

NCT03062033

EVA-19350

Details and patient eligibility

About

Prospective study to quantify the prevalence of possible tardive dyskinesia (TD) in outpatient psychiatry practices in the United States (US), as well as to describe the associated disease burden in a cohort of patients with one or more psychiatric disorders and a cumulative lifetime exposure to antipsychotic medication of three months or more.

Enrollment: 70 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient has a cumulative lifetime exposure to antipsychotic medication of three months or more
• Patient has a clinician confirmed diagnosis of one or more psychiatric disorder(s), as defined in the DSM-5
• Patient has a usual care clinic visit scheduled during the study recruitment window (i.e. a pre-defined 2-week period)
• Patient is able to read and understand English
• Patient is willing and able to comply with the study requirements

Exclusion criteria

• Patient is unable to provide informed consent.

Trial design

70 participants in 2 patient groups

Cohort 1

Description:

Patients without visible signs of involuntary movements (possible TD) at time of clinician assessment

Cohort 2

Description:

Patients with visible signs of involuntary movements (possible TD) at the time of clinician assessment